Nemaura Medical Inc. (NMRD)
| Market Cap | 4.04K |
| Revenue (ttm) | n/a -84.7% |
| Net Income | -10.65M |
| EPS | -0.38 |
| Shares Out | 40.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,004 |
| Open | 0.0001 |
| Previous Close | 0.0001 |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | n/a |
| Beta | -99.99 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About Nemaura Medical
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based ... [Read more]
News
Nemaura Medical decides to accept Nasdaq determination to delist
Nemaura Medical is providing an update regarding recent decisions that will impact Nemaura Medical’s listing status on The Nasdaq Capital Market and our broader strategic direction. The company said, ...
Important Update on Listing Status and Strategic Direction
Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, i...
Nemaura Medical receives positive Nasdaq listing decision
Nemaura Medical announces that the Nasdaq Hearings Panel granted the Company’s request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on ...
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision
Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthc...
Nemaura Medical secures $10M non-dilutive credit facility
Nemaura Medical announced the execution of a strategic agreement for a $10 million credit facility which is expected to support the Company’s strategic growth plans. Recognizing the challenges associa...
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth
Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthc...
Nemaura Medical rating moved to under review at H.C. Wainwright
H.C. Wainwright analyst Yi Chen moved Nemaura Medical’s rating to under review following the fiscal Q2 report ahead of the Nasdaq hearing.
Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
Company CEO to discuss development at 1pm EST on 15 th November 2023, at the Sidoti Virtual Investor Conference
Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update
Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a dai...
Nemaura Medical Quarterly report: Q2 2024
Nemaura Medical has published its Q2 2024 quarterly earnings report on November 13, 2023.
Nemaura Medical Earnings release: Q2 2024
Nemaura Medical released its Q2 2024 earnings on November 13, 2023, summarizing the period's financial results.
Nemaura Medical appoints Nikolai Rozanov as strategic adviser in AI
Nemaura Medical announced the appointment of Nikolai Rozanov as strategic adviser in AI development. Rozanov is a specialist in the field of artificial intelligence and was selected for inclusion by…
Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.
LOUGHBOROUGH, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive w...
Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference
Loughborough, England, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic ...
Nemaura Medical provides update on Nasdaq compliance status, process
Nemaura Medical provided an update regarding the status of its compliance with Nasdaq continued listed standards and anticipated next steps to maintain its listing on The Nasdaq Capital Market. The…
Nemaura Medical Provides Update on Nasdaq Compliance Status and Process
LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive w...
Nemaura Medical Announces Interim Results from its Collaboration with the UK's National Health Service on its Metabolic Health & Weight Loss Program
LOUGHBOROUGH, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive w...
Nemaura Medical Announces Participation at HLTH 2023, Las Vegas
LOUGHBOROUGH, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive w...
Nemaura Medical completes 100 patient study for sugarBEAT 24-hour wear
Nemaura Medical announced it has recently completed a 100-patient study across 4 cohorts of 25 diabetic patients for sugarBEAT(R) and provided interim results. The Company has previously received CE a...
Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results
LOUGHBOROUGH, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive ...
Nemaura Medical price target lowered to $2.50 from $7 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Nemaura Medical to $2.50 from $7 and keeps a Buy rating on the shares. The firm expects the company…
Nemaura Medical announces SFDA approval of sugarBEAT
Nemaura Medical announced SFDA approval of sugarBEAT, its non-invasive wearable glucose sensor. The news comes following over a year of liaisons with the SFDA through TPMENA, the Company’s licensee in...
Nemaura Medical Announces SFDA Approval of sugarBEAT®
Loughborough, England, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a dai...
Nemaura Medical reports Q1 EPS (9c) vs. (16c) last year
Cash and cash equivalents at 30th June 2023 were approximately $4m, and the Company announced on 11th August 2023 that it had secured a further $6.5m in clean debt. Published…
Nemaura Medical Quarterly report: Q1 2024
Nemaura Medical has published its Q1 2024 quarterly earnings report on August 14, 2023.